Home
Technology
Drug Delivery Platform
Sensitive DNA/RNA Synthesis Platform
Products & Services
COVID-19 Research Support
Liposomes Drug Delivery Services For COVID-19
COVID-19 mRNA Vaccine Development Services
Custom Oligo Synthesis Services For COVID-19 Research
Oligo Synthesis Service
Custom DNA Oligonucleotides Synthesis
Custom RNA Oligonucleotides Synthesis
Custom mRNA Synthesis
DNA/RNA Modification
Custom Oligo Synthesis
Antisense Oligonucleotides Synthesis
Oligo Modifications
GMP Oligonucleotide Manufacturing Services
CpG oligonucleotides (CpG ODN)
Diagnostic Probes & Oligos
Custom LNA Synthesis
Custom BNA Oligonucleotide Synthesis
Oligonucleotide Conjugation Services
DNA/RNA Synthesis Reagents
RNA Phosphoramidites
Sensitive DNA/RNA Synthesis
Dye Phosphoramidites
Label Phosphoramidites
Linker Phosphoramidites
Spacer Phosphoramidites
CPGs for oligo synthesis
Oligo Analysis & Purification
siRNA Products & Services
lncRNA research
Predesigned siRNA Library
shRNA plasmid expression vector
siRNA Screening Services
Custom siRNA
Custom Chemically Modified siRNA
Custom Fluorescence-labeled siRNA
siRNA Control
siRNA Sets
Drug Delivery System
Exosome
Liposomes
GalNAc-siRNA Conjugates
Antibody-siRNA Conjugates
Peptide-siRNA conjugates
Polymer-siRNA Conjugates
Cholesterol-siRNA Conjugates
Nanoparticle-siRNA Conjugates
Aptamer-siRNA conjugates
Folic acid–siRNA conjugates
CpG-siRNA Conjugates
Dynamic Polyconjugates (DPC)
Professional Support for mRNA Vaccines
Support
News
mRNA-1647,the first infectious disease mRNA vaccine to enter the second phase of research
Onpattro, The First FDA-approved RNAi Drug
FDA approves first RNAi treatment for inherited rare diseases
Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)
Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition
Resources
Explore & Learn
Bioinformatics Online Tools
FAQs
FAQs of siRNA
Events
Aptamers 2022
Oligo 2022 Oxford: Antisense & Therapeutic Nucleic Acids
CPhI North America
TIDES USA: Oligonucleotide & Peptide Therapeutics Conference
Ordering
About Us
Contact Us
Careers
Home
Support
Support
Support
News
Resources
FAQs
*
Only for research. Not suitable for any diagnostic or therapeutic use.
CONTACT US
Event information
Aptamers 2022
April 4-5, 2022
Oxford, UK
Oligo 2022 Oxford:
Antisense & Therapeutic Nucleic Acids
April 6-7, 2022
St Hilda's College, Oxford, UK